Efficacy and safety of @entity2177 for prophylaxis of @entity8999 virus-associated XXXX in allogeneic hematopoietic stem cell transplantation recipients.

@entity1 @entity8999 @entity294 @entity2177 @entity2887 @entity2132 @entity2718 @entity2335 @entity2259
Polyoma virus BK-induced @entity2335 is an important cause of morbidity after hematopoietic stem cell transplantation (HSCT). @entity2887 have been shown in vitro to inhibit BK viral replication by direct inhibition of the BK-encoded DNA gyrase. We hypothesized that extended prophylaxis with @entity2177 may decrease the incidence of severe (grades 3 and 4) @entity8999 -associated @entity2335 (sBKHC) after HSCT. We retrospectively collected @entity1 and transplant data, as well as incidence of sBKHC, for all consecutive @entity1 undergoing allogeneic HSCT between June 2006 and August 2010 at our institution. Prophylaxis for sBKHC with @entity2177 500 mg orally twice daily from day 0 until day 60 had been instituted in March 2009, delimiting a group receiving @entity2177 prophylaxis (CP) or no prophylaxis (NP). We compared the cumulative incidence of sBKHC in CP and NP, including death in absence of sBKHC as a competing risk. Ninety-two consecutive @entity1 were included in the analysis, 44 in CP and 48 in NP. Median age of @entity1 was 50 years (range: 19-70), and 47% received a myeloablative conditioning regimen. The cumulative incidence of sBKHC was significantly reduced in CP (2.6% versus 20.9%, P  =  .01). Multivariate Cox regression analysis revealed that assignment to CP and concomitant @entity2132 ( @entity2132 ) were the only factors independently associated with the occurrence of sBKHC. @entity1 in CP did not experience a higher risk of @entity2718 @entity294 and were less likely to develop episodes of @entity2259 . @entity2177 prophylaxis appears safe and effective in reducing the incidence of severe BKHC after allogeneic HSCT.
